National Pharmaceuticals Corp
PINK SHEETS : NFRM

February 24, 2011 11:43 ET

National Pharmaceuticals Enters Negotiations over Licensing of Revolutionary New Treatment for Tissue Healing and Chronic Pain Management

MIAMI, FLORIDA--(Marketwire - Feb. 24, 2011) - National Pharmaceuticals Corp. (PINK SHEETS:NFRM) or the "Company" announced today that it has entered into negotiations over the licensing of a novel growth factor code name "GLB333". The new growth factor is believed to have profound effect in the treatment of many diseases including tissue injury, muscle rebuilding, skin regeneration and chronic pain due to tissue injury.

According to the company, negotiations between a leading pharmaceutical research and development company and NFRM are well underway and a letter of intent is expected to be entered into on or before March 04, 2011.

"If everything goes according to our discussions, we should have a letter of intent within next two weeks or sooner," said Elaine Affleck, President of National Pharmaceutical Corp. "This is a tremendous opportunity for our company and our shareholder to be at the forefront of this novel treatment for disabiliating diseases that affects more than 10 million people," further added Ms. Affleck.

About National Pharmaceuticals Corp.

National Pharmaceuticals Corp. is a Pharmaceutical Research and Development Corporation focused on leading edge technologies for treatment of human diseases. The company has embarked into the business of licensing mid stage development drugs for further development and marketing worldwide.

Forward-looking Statements – Important Information about Forward-Looking Statements in this press release is within the meaning of the Private Securities Litigation Reform Act of 1995. Words such as "anticipate", "believe", "estimate", "expect", "intend" and similar expressions, as they relate to the company or its management, identify forward-looking statements. These statements are based on current expectations, estimates and projections about the company's business based, in part, on assumptions made by management. These statements are not guarantees of future performance and involve risks, uncertainties and assumptions that are difficult to predict. Therefore, actual outcomes and results may, and probably will, differ materially from what is expressed or forecasted in such forward-looking statements due to numerous factors, including those described above.

Contact Information

  • National Pharmaceuticals Corporation
    Elaine Affleck
    (954) 903-1967